These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 25053345)

  • 1. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
    Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
    Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
    Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
    Oncotarget; 2015 Aug; 6(25):21740-54. PubMed ID: 25844599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
    Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
    Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic.
    Samsonov R; Shtam T; Burdakov V; Glotov A; Tsyrlina E; Berstein L; Nosov A; Evtushenko V; Filatov M; Malek A
    Prostate; 2016 Jan; 76(1):68-79. PubMed ID: 26417675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
    O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L
    Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways.
    Lichner Z; Ding Q; Samaan S; Saleh C; Nasser A; Al-Haddad S; Samuel JN; Fleshner NE; Stephan C; Jung K; Yousef GM
    J Pathol; 2015 Oct; 237(2):226-37. PubMed ID: 26011734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
    Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
    Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome-derived miRNAs and ovarian carcinoma progression.
    Vaksman O; Tropé C; Davidson B; Reich R
    Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
    Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
    PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
    Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
    PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
    Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
    Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
    Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
    Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.